1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsHepConnect is sponsored by Gilead Sciences. A five-year initiative addressing the intersecting opioid and hepatitis C virus (HCV) epidemics in Indiana, Kentucky, North Carolina, Tennessee, and West Virginia.
Get alerted about grants like this
Get emailed when new opportunities from “Gilead Sciences” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Gilead Sciences: HepConnect Addressing the Increase in Hepatitis C Fueled by the Opioid Crisis HepConnect supports programs and services designed to reach people in need.
In response to the intersecting opioid and hepatitis C virus (HCV) epidemics in the U.S., in 2019 we launched HepConnect, a five-year, multi-million-dollar initiative to help address the increase in HCV and support community partnerships in Indiana, Kentucky, North Carolina, Tennessee and West Virginia.
HepConnect has three areas of focus: Expand Screening and Linkage to Care Support Harm Reduction and Community Education Activate Healthcare Infrastructure Expand Screening and Linkage to Care HepConnect supports local community partnerships to expand testing for the virus and support access to healthcare. HCV does not always cause symptoms immediately. Testing is the first step to ensure people receive treatment.
Access to healthcare can be difficult in rural areas, including much of greater Appalachia. Many residents of the region lack insurance coverage, limiting their ability to get the care they need. Support Harm Reduction and Community Education Opening doors to harm reduction services can help reduce HCV transmission.
HepConnect helps community partnerships and prevention programs: Implement and expand evidence-based, practical strategies that can have a real impact on affected populations and their surrounding communities, including Medication Assisted Treatment (MAT) programs and Syringe Exchange Programs (SEPs). Remove barriers to services that are a critical part of the continuum of care and proven to reduce HCV rates.
Make harm reduction services available to all who need them. Activate Healthcare Infrastructure Building resources, know-how and capacity in communities where the need is greatest can make a difference. HepConnect works to: Educate and expand the number of healthcare providers able to care for people with HCV across the region.
Support the implementation of telemedicine and other innovative programs that reach people where they are. Develop local solutions, as they can be the most effective in combating rising rates of HCV. HepConnect grantees are making an impact.
According to the current listing, eligibility includes: Local community partnerships and prevention programs in Indiana, Kentucky, North Carolina, Tennessee, and West Virginia working to expand HCV testing, support harm reduction services, and activate healthcare infrastruct…. Confirm the full requirements in the official notice before applying.
HepConnect is funded by Gilead Sciences. Verify program details on the funder's official page before applying.
This opportunity targets applicants in North Carolina, West Virginia, Tennessee, Kentucky, and Indiana. Check the official notice for exact location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Schmidt Sciences opened a 'Scaling AI Safety for a Multi-Agent World' program with awards up to $1 million and an August 8, 2026 deadline. Against a backdrop of federal research slowdowns, here is why private science philanthropy matters more than ever, how these funders differ from federal agencies, and how researchers should approach them.
Read articleNSF's Arctic Research Opportunities solicitation funds roughly 75 awards a year — up to $50 million — across six program areas from natural sciences to social sciences to the Arctic Observing Network. The July 15, 2026 target date is not a hard deadline, and understanding that distinction is the first strategic decision an Arctic researcher makes. Here is how the six doors differ and how to choose the right one.
Read articleSchmidt Sciences' 2026 Science of Trustworthy AI RFP closes May 17 with two funding tiers — up to $1M (Tier 1) and $1–5M+ (Tier 2) over 1–3 years, with a 10% indirect cost cap. The three research aims target misalignment under distribution shift, predictive-validity evaluations, and oversight of superhuman systems. Here is why the structure favors team-based proposals.
Read article